Hypertension, Pulmonary: Clinical Trials

781 completed, 217 unknown, 196 recruiting, 173 terminated. 336 Not applicable, 285 Phase 2, 215 Phase 3, 151 Phase 1, 123 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	336	Completed 150, Unknown 73, Recruiting 45, Not yet recruiting 22, Terminated 16, Withdrawn 15, Active not recruiting 9, Enrolling by invitation 4, Suspended 2
Phase 2	285	Completed 138, Terminated 58, Recruiting 26, Withdrawn 24, Unknown 18, Not yet recruiting 12, Active not recruiting 9
Phase 3	215	Completed 109, Terminated 43, Recruiting 18, Unknown 16, Withdrawn 14, Active not recruiting 10, Not yet recruiting 3, Enrolling by invitation 1, Suspended 1
Phase 1	151	Completed 94, Terminated 15, Recruiting 14, Withdrawn 13, Unknown 8, Not yet recruiting 6, Active not recruiting 1
Phase 4	123	Completed 59, Terminated 27, Unknown 12, Recruiting 10, Withdrawn 9, Active not recruiting 3, Not yet recruiting 3
Early Phase 1	18	Completed 5, Terminated 5, Recruiting 3, Unknown 3, Not yet recruiting 1, Withdrawn 1

Follow Hypertension, Pulmonary: new trials by email Literature Review of Hypertension, Pulmonary trials Research Report on Hypertension, Pulmonary

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets MN-08 24 mg/day, MN-08 60 mg/day - Pulmonary Arterial Hypertension	Phase 1	Not yet recruiting	Guangzhou Magpie Pharmaceuticals Co., Ltd.	16	2027-09-01	2026-09-14
What is the Role of the Exposome in Pulmonary Hypertension Questionnaires, Samples - Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH)		Not yet recruiting	Poitiers University Hospital	150	2027-01-01	2026-07-22
GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry GLP-1 / GIP receptor agonist - Heart Failure With Preserved Ejection Fraction, Obesity		Not yet recruiting	Miedziowe Centrum Zdrowia SA	150	2027-01-01	2026-08-26
Right Heart and Lung Blood Flow During Exercise (RIGHT-NET 2.0) Right Ventricular Dysfunction, Cardiopulmonary Diseases		Not yet recruiting	IRCCS SYNLAB SDN	2000	2027-01-01	2026-10-01
Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension Protek Solo Transseptal Cannula - Lung Transplant, Pulmonary Hypertension	Phase 1	Recruiting	Mayo Clinic	4	2026-12-11	2026-07-31
A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041) Sotatercept, Placebo - Pulmonary Hypertension	Phase 3	Not yet recruiting	Merck Sharp & Dohme LLC	352	2026-11-26	2026-10-06
A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea Pulmonary Arterial Hypertension		Not yet recruiting	Janssen Korea, Ltd., Korea	333	2026-11-02	2026-10-22
Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis Hyperpolarized 129 Xenon Gas - Interstitial Lung Disease, Pulmonary Hypertension	Phase 2	Not yet recruiting	Bastiaan Driehuys	51	2026-11-01	2026-09-15
TEPH: Telaglenastat Efficacy in Pulmonary Hypertension Telaglenastat - Pulmonary Hypertension	Phase 1 / Phase 2	Not yet recruiting	Chan, Stephen, MD, PhD	28	2026-11-01	2026-09-17
Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) Dopamine administration, Norepinephrine - Hypotension and Shock, Pulmonary Hypertension of the Newborn (PPHN)	Phase 4	Recruiting	University of California, Davis	30	2026-10-30	2026-08-18
Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO) Discontinuation of parenteral prostacyclins analogues or selexipag - Pulmonary Arterial Hypertension	Not applicable	Not yet recruiting	University of Alberta	78	2026-10-30	2026-09-23
Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH) IKT-001 - Pulmonary Arterial Hypertension (PAH)	Phase 3	Not yet recruiting	Inhibikase Therapeutics	484	2026-10-23	2026-06-08
Pulmonary Hypertension (PH) Biorepository for Translational Research Pulmonary Hypertension		Recruiting	National Institutes of Health Clinical Center (CC)	1000	2026-10-19	2026-10-22
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037) Sotatercept, Background PAH Therapy - Pulmonary Arterial Hypertension	Phase 4	Recruiting	Merck Sharp & Dohme LLC	30	2026-10-08	2026-10-22
Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Pulmonary Vascular Disease (PVD) 6-minute walk distance (6MWD) test on ambient conditions, 6-minute walk distance (6MWD) test with supplemental oxygen (LOX) - Pulmonary Vascular Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH)	Not applicable	Recruiting	Silvia Ulrich Somaini	40	2026-10-01	2026-09-09
PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial Hypertension Standardized Overnight Sleep and Cardiorespiratory Monitoring - Pulmonary Arterial Hypertension (PAH), Sleep-disordered Breathing (SDB)		Recruiting	Chinese Pulmonary Vascular Disease Research Group	1500	2026-10-01	2026-10-01
Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Chronic Lung Diseases 6-minute walk distance (6MWD) test on ambient conditions, 6-minute walk distance (6MWD) test with supplemental oxygen (LOX) - Pulmonary Vascular Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH)	Not applicable	Recruiting	Silvia Ulrich Somaini	40	2026-10-01	2026-09-09
Post Market Clinical Follow-up to Assess the Portable Nitric Oxide Generation and Delivery System (INOwill N200) for the Treatment of Neonatal Hypoxic Respiratory Failure Complicated by Pulmonary Hypertension Nitric Oxide Generator and Delivery System - Persistent Pulmonary Hypertension of the Newborn, Hypoxic Respiratory Failure		Not yet recruiting	Novlead Inc.	50	2026-10-01	2026-09-24
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension GLP-1 agonist - Pulmonary Arterial Hypertension	Phase 2	Not yet recruiting	Imperial College London	32	2026-10-01	2026-07-30
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease TX000045 - Hypertension, Pulmonary, Lung Diseases, Interstitial	Phase 2	Recruiting	Tectonic Operating Company, Inc.	25	2026-10-01	2026-09-08

Showing 20 of 1601. Sign in to see all of them.

Narrower conditions

Pulmonary Arterial Hypertension (692)  ·  Familial Primary Pulmonary Hypertension (99)  ·  Heart Failure (88)  ·  Pulmonary Disease, Chronic Obstructive (69)  ·  Lung Diseases, Interstitial (58)  ·  Hypoxia (42)  ·  Heart Defects, Congenital (40)  ·  Motor Activity (40)  ·  Persistent Fetal Circulation Syndrome (40)  ·  Hypertension (34)  ·  Lung Diseases (34)  ·  Scleroderma, Systemic (34)  ·  Altitude Sickness (32)  ·  Anemia, Sickle Cell (30)

Broader conditions

Respiratory Tract Diseases (1591)  ·  Lung Diseases (1567)  ·  Cardiovascular Diseases (1043)  ·  Vascular Diseases (1013)  ·  Hypertension (989)  ·  Pathological Conditions, Signs and Symptoms (259)  ·  Heart Diseases (197)  ·  Pathologic Processes (182)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (181)  ·  Respiration Disorders (97)  ·  Disease Attributes (96)  ·  Chronic Disease (80)  ·  Signs and Symptoms (78)  ·  Congenital Abnormalities (77)

Interventions

Sildenafil Citrate (86)  ·  treprostinil (65)  ·  Bosentan (45)  ·  Iloprost (40)  ·  ambrisentan (39)  ·  Tadalafil (34)  ·  riociguat (31)  ·  macitentan (26)  ·  ACE-011 (21)  ·  selexipag (18)  ·  Blood Specimen Collection (16)  ·  Exercise (16)  ·  Epoprostenol (14)  ·  Echocardiography (13)  ·  Nitric Oxide (12)

Sponsors

Actelion (72)  ·  United Therapeutics (60)  ·  University of Zurich (53)  ·  Bayer (45)  ·  Medical University of Graz (23)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (23)  ·  Assistance Publique - Hôpitaux de Paris (22)  ·  National Heart, Lung, and Blood Institute (NHLBI) (20)  ·  Heidelberg University (18)  ·  Mayo Clinic (17)  ·  Merck Sharp & Dohme LLC (17)  ·  Assiut University (15)  ·  GlaxoSmithKline (14)  ·  Pfizer (14)  ·  University of Giessen (14)

Countries

United States (623)  ·  Germany (212)  ·  France (180)  ·  United Kingdom (179)  ·  Canada (147)  ·  China (138)  ·  Spain (125)  ·  Italy (124)  ·  Belgium (107)  ·  Austria (99)  ·  Switzerland (93)  ·  Australia (91)  ·  Poland (88)  ·  Israel (87)  ·  Netherlands (83)

Top investigators

Horst Olschewski, MD (18)  ·  Silvia Ulrich, Prof. Dr. (17)  ·  Silvia Ulrich, Prof. (15)  ·  Ashika Ahmed, MD (8)  ·  Rodrigo Hoyos (7)  ·  Silvia Ulrich (7)  ·  Rajan Saggar, MD (6)  ·  Silvia Ulrich, MD (6)  ·  Steeve Provencher, MD, MSc (6)

Results publications

PMID 16982941, PMID 26589907, PMID 27162632, PMID 20175775, PMID 24578332, PMID 24916507, PMID 27263466, PMID 34353714, PMID 17418297, PMID 18277824, PMID 20585012, PMID 21680644, PMID 22280813, PMID 22281797, PMID 22354598, PMID 23164592, PMID 23403476, PMID 23883377, PMID 23883378, PMID 23883383, PMID 25372980, PMID 25496504, PMID 26113687, PMID 26135803, PMID 26231884, PMID 26308684, PMID 26320113, PMID 27067478, PMID 27326239, PMID 27444506, PMID 27457511, PMID 28775050, PMID 29447737, PMID 29501590, PMID 29531764, PMID 30545968, PMID 31109190, PMID 31487545, PMID 31538282, PMID 31722151, PMID 31908813, PMID 32974687, PMID 33651671, PMID 34379314, PMID 34727317, PMID 34848133, PMID 35256218, PMID 35628896, PMID 35819570, PMID 35990987

NIH funding

2018 (24), 2023 (16), 2025 (10), 2008 (7), 2014 (7), 2015 (7), 2017 (7), 2016 (6), U10HD021385 (6), U10HD027880 (6), 2009 (5), U10HD027904 (5), U10HD034216 (5), M01RR000070 (4), M01RR000750 (4)